Towards bone graft manufacturing via endochondral ossification by Tonnarelli, Beatrice
Inauguraldissertation 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
von 
	
  
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   Original	
  document	
  stored	
  on	
  the	
  publication	
  server	
  of	
  the	
  University	
  of	
  Basel	
  	
  
edoc.unibas.ch	
  	
  
	
  
	
  This	
  work	
  is	
  licenced	
  under	
  the	
  agreement	
  „Attribution	
  Non-­‐Commercial	
  No	
  Derivatives	
  –	
  2.5	
  Switzerland“.	
  The	
  complete	
  text	
  may	
  be	
  viewed	
  here:	
  	
  
creativecommons.org/licenses/by-­‐nc-­‐nd/2.5/ch/deed.en	
  	
  
Towards bone graft manufacturing 
via endochondral ossification 
Beatrice Tonnarelli 
aus Italien 
Basel, 2012 
Attribution-Noncommercial-No Derivative Works 2.5 Switzerland
You are free:
to Share — to copy, distribute and transmit the work 
Under the following conditions:
Attribution. You must attribute the work in the manner specified by the author or 
licensor (but not in any way that suggests that they endorse you or your use of the 
work). 
Noncommercial. You may not use this work for commercial purposes.
No Derivative Works. You may not alter, transform, or build upon this work. 
• For any reuse or distribution, you must make clear to others the license terms of this work. The best way 
to do this is with a link to this web page. 
• Any of the above conditions can be waived if you get permission from the copyright holder. 
• Nothing in this license impairs or restricts the author's moral rights. 
Quelle: http://creativecommons.org/licenses/by-nc-nd/2.5/ch/deed.en Datum: 3.4.2009
Your fair dealing and other rights are in no way affected by the above. 
This is a human-readable summary of the Legal Code (the full license) available in German: 
http://creativecommons.org/licenses/by-nc-nd/2.5/ch/legalcode.de
Disclaimer:
The Commons Deed is not a license. It is simply a handy reference for understanding the Legal Code (the 
full license) — it is a human-readable expression of some of its key terms. Think of it as the user-friendly 
interface to the Legal Code beneath. This Deed itself has no legal value, and its contents do not appear in 
the actual license. Creative Commons is not a law firm and does not provide legal services. Distributing of, 
displaying of, or linking to this Commons Deed does not create an attorney-client relationship. 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät 
auf Antrag von 
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
	
  	
  	
  	
  	
  
Prof. Ueli Aebi        Prof. Dr. Giuseppe Peretti  Prof. Ivan Martin 
Basel, den 21/06/2011 
Prof. Dr. Martin Spiess 
	 	 	 	 	 	 	 	 	 	 Basel, June 6th 2011
alla mitica bici benotto
le reve, c’est tout - 
la technique, ca s’apprend.
jean t inguely
Table of Contents
Introduction
 2
1. Long bone and articular cartilage development
 2
1.1 Endochondral bone formation
 3
1.2 Focusing on molecular pathways 
 7
2. Repair capacity of skeletal tissue
 9
2.1 …at the bone side…
 9
2.2 …at the cartilage side…
 9
3. Skeletal defects: reparative and regenerative clinical strategies
 10
3.1 Conventional techniques
 10
3.2 Tissue engineering approach
 11
3.3 Developmental engineering concept
 15
4. Experimental work
 16
Chapter I
 21
Engineering Cartilaginous Template For Endochondral Ossification
 21
Chapter II
 32
Novel Paradigm For Cartilage Graft Development Directly In 3D Scaffolds In Single 
Closed Bioreactor System
 32
Chapter III
 44
Model System To Control Cell Condensation Directly In 3D Scaffold In Bioreactor Sys-
tem
 44
Conclusions and final remarks
 52
1. Summary: aims and results of the experimental work
 52
2. Relevance of the study and future perspectives
 53
Acknowledgements
 55
Introduction
1. Long bone and articular cartilage development 
Skeletal structures in the body withstand load bearing, allow adjacent muscles to move them in coordination 
with specialized joint structures, protect adjacent organs, and serve as mineral reservoir that can be mobi-
lized on metabolic demand. 
Location and type of bone and articular cartilage structures in the body select their initial development and 
ultimate function. Sizes and shapes of bones need to be carefully controlled and tuned to exert specific 
functions in efficient manner and in specific environments. Therefore bone is a dynamic tissue with a unique 
capacity to remodel. 
On the contrary, cartilage of the skeletal system is a quiescent connective tissue with poor remodeling activ-
ity but important load bearing and motility functions.
Hormone/growth factor signaling pathways tightly coordinate both skeletal development and remodeling, 
throughout the individual lifespan. Among several paracrine morphogens, bone morphogenetic proteins 
(BMPs), Wnts, fibroblast growth factors (FGFs) and hedgehog proteins are essential for normal bone forma-
tion. Moreover, systemic factors such as growth hormone, thyroid hormone, oestrogen, androgen, vitamin D 
and glucocorticoids contribute to control skeletal growth (Kronenberg 2003).
During embryogenesis, skeletal formation begins when cells from mesenchyme start to condense (Hall and 
Miyake 2000).
For all bones of axial system, cartilage is the first skeletal tissue to be formed by mesenchymal progenitors 
and subsequently remodeled into bone through a program called endochondral route (Figure 1a).
On the contrary, flat bones such as skull develop via direct differentiation of condensed mesenchymal cells 
into bone forming osteoblasts bypassing cartilaginous intermediate and undergoing membranous or in-
tramembranous ossification (Quintana, zur Nieden and Semino 2009) (Figure 1b).
The two developmental processes differ from (i) location and type of skeletal elements where they occur (flat 
or long bones), (ii) key morphogenetic pathways involved, (iii) intermediate and terminal cell differentiation 
stages and (iv) extracellular matrix (ECM) composition. These structural and functional differences are cru-
cial aspects for repair processes and regenerative medicine approaches.
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1.1 Endochondral bone formation
Long bone and axial skeleton formation occurs through a process called endochondral ossification, as a 
result of coordinated cell migration, proliferation, differentiation, and remodeling of cartilaginous matrix tem-
plates. In the developing limb, early bone formation begins with migration of undifferentiated mesenchymal 
cells from the mesoderm to the limb bud following morphogenetic signals made by apical ectodermal re-
gion (Sundelacruz and Kaplan 2009). 
Rapidly proliferating mesenchymal cells that have been recruited into the bone-forming region commit to 
chondrogenic lineage, aggregate to form compact nodules, and secrete extra cellular matrix (ECM) firstly 
enriched in collagen type I and hyaluronan (ten Berge, et al. 2008) (Figure 2).
This condensation phase is associated with a decrease in extracellular space and involves changes in cell–
cell and cell–matrix interactions, which are mediated by adhesion molecules including N-cadherin and fi-
bronectin. Condensed cells keep on proliferating and differentiating to form a soft callus (cartilage anlage) 
that provides mechanical support while acting as a template for future bone deposition. Chondrocyte differ-
entiation is characterized by synthesis of cartilage-supporting matrix, including collagens II, IX, and XI, and 
aggrecan and other proteoglycans (Figure 2). 
3
Figure 1 Mesenchymal cells condense at sites of future bones. In endochondral ossification route (a), first a cartilage model (anlage) is 
formed; this tissue undergoes hyperthrophy while a collar of bone appears at the periphery and vessels ingrowth begins, thanks to the 
developing gradients of angiogenic factors such as vascular endothelial growth factor (VEGF); finally, hyperthrophic cartlage is replaced 
by marrow and bone and growth plates are formed. In membranous ossification process (b), direct differentiation of mesenchymal cells 
to osteoblasts and production of bone matrix occurs (adapted from Zelzer and Olsen 2003 ). 
a
b
Chondrocytes mature further, and undergo hypertrophy. The composition of the ECM changes due to chon-
drocyte secretion of collagen type X and matrix metalloprotease 13 (MMP13) (Figure 2). Late differentiated 
chondrocytes positioned in the centre of the cartilaginous mould ultimately stop proliferating and become 
apoptotic. On the contrary, the ones in closed proximity with the external part, the perichondrium, undergo a 
different fate and perform multiple tasks as they are exposed to unique matrix components and cellular 
crosstalks. Upon transitional chondrogenic activity, these latter cells are prompted to differentiate towards 
the osteogenic lineage actively contributing to bone formation as they mineralize the ECM by producing 
bone sialo-protein (BSP) and depositing hydroxyapatite. Thanks to the localization and dual differentiation 
potential, they have been named “borderline” chondrocytes and they contribute to the formation of the ex-
ternal bone collar (Figure 3).
Interestingly, chondrocytes contribute to tissue formation and to tissue removal, respectively at bony collar 
and growth plate (Bianco, et al. 1998). Even if cartilage itself is characterized by its avascular nature, termi-
nal hypertrophic chondrocytes become actually a target for vascular invasion by expressing high levels of 
angiogenic molecules, such as vascular endothelial growth factor (VEGF). Thus, capillaries first grow around 
the cartilage anlage and then invade the remodeled matrix by crossing the developing bone collar. Initial 
blood vessel invasion of the cartilaginous bone model occurs in parallel with its transformation into the pri-
mary OSSIFICATION center (POC) (Figure 3). ECM degradation and angiogenic gradients allow for vascular 
invasion and recruitment of osteoblastic, osteoclastic, and hematopoietic precursors from peripheral blood 
stream. Early osteoblasts precursors, characterized by the expression of the primitive marker Osterix and in 
closed association with pericytes, translocate into the developing POC and contribute to the stroma or pro-
duce trabecular bone.  The first committed osteoblast lineage cells localize in the perichondrium surround-
ing the hypertrophic cartilage whereas mature osteblastic cells (expressing collagen type I) are present in 
the cortical bone surfaces. As well as chondrocytes, osteoblastic cells display differential destinies depend-
ing on their stage of maturation and location (Maes et al. 2010) (Figure 4).
The osteoclasts, bone remodeling cells, degrade most of the matrix surrounding hypertrophic chondrocytes 
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Figure 2 Extra cellular matrix (ECM) changes during endochondral ossification. Cells produce and remodel the matrix, which, in turn,  
provides physical and biochemical stimuli to the cells (adapted from Sundelacruz and Kaplan 2009).
leaving fragments that serve as scaffolding for deposition of bone matrix by the osteoblasts. As the bone 
enlarges, haematopoietic stem cells interact with the stroma and become established in spaces between 
the bony trabeculae creating the main site for haematopoiesis in post-natal life (Figure 3).  
At this stage of the endochondral route, hypertrophic cartilage is replaced by marrow and bone, along with 
vascular invasion, and in forming long bony parts 
epiphyses and metaphyses at each end and diaphy-
sis in between are established (Figure 3).
The epiphyses play a key role in determining the 
transverse and spherical growth of the ends of the 
bone, the shaping of the articular surfaces, and the 
longitudinal growth of the metaphyses and the dia-
physis. Growth plates are finally formed at the inter-
face between metaphysis and epiphysis (Figure 5) 
(Shapiro 2008). 
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Figure 3  “Endochondral bone development. (a, b) Chondrocytes differentiate 
within mesenchymal condensations to form cartilage anlagen of future bones. 
(c, d) Coincident with the appearance of the perichondrial bone collar, 
chondrocytes in the central anlage undergo hypertrophy followed by invasion 
of vascular and osteoblastic cells from the collar (e) and formation of the 
primary ossification center (f). This process expands toward the ends of the 
bone, eventually forming mature growth plates (h). Secondary ossification 
centers later form in the epiphyseal cartilage (i).” (from Horton and Degnin 
2009)
Figure 4 “Schematic outline of the events taking place 
during the initial invasion of the cartilaginous bone model and 
its transformation into the primary ossification center (POC). 
Chondro-perichondrial progenitors (Col2+, green) give rise 
to cells in the central growth cartilage. The first committed 
osteoblast lineage cells appear in the perichondrium 
surrounding the middiaphyseal hypertrophic cartilage. Early 
cells of the lineage, represented by the Osx-expressing 
osteoblast precursors (Osx+, yellow), move into the 
developing POC and populate it as stromal cells or 
differentiate further to become bone-forming trabecular 
osteoblasts. The entrance of the osteoblast precursors into 
the POC coincides with the initial invasion by blood vessels 
(red) and osteoclasts (blue), and is associated with a 
pericytic localization of a subset of the precursors onto the 
endothelium. In contrast, differentiated cells within the 
perichondrium/periosteum (Col1+ mature osteoblasts, 
orange) are not found in vessel-covering positions and do 
not have the capacity to translocate into the POC. These 
osteoblasts are retained on and within the cortical bone 
surfaces” (from Maes et al. 2010) 
Figure 5  “Growth plate structure. The growth plate is dynamic 
with a leading edge (green) where chondrocytes proliferate and a 
trailing edge (brown) where cartilage template generated by the 
proliferating and terminally differentiating chondrocytes is degraded 
by invading vascular cells (red) and replaced by the expanding 
ossification front (blue)” (from Horton and Degnin 2009) 
A portion of chondrocytes (columnar chondrocytes) in the centre of the developing bone assumes a flat-
tened, discoid shape and form columns oriented along the axis of bone lengthening, a process they control 
primarily by the rate of differentiation into hypertrophic chondrocytes. 
The soft transient cartilaginous callus has been  gradually replaced by hard woven bone, with the exception 
for articular cartilage that is stable at the joint site (Kronenberg 2003). As a matter of fact, each epiphysis 
develops into: i) cartilage adjacent to the joint space, the articular cartilage, characterized by quiescent 
chondrocyte cell population and collagen type II rich matrix ii) cartilage adjacent to the metaphysis, the 
growth plate, and iii) cartilage between the articular cartilage and the physeal cartilage, the epiphyseal car-
tilage, which will form a secondary ossification center upon invasion by vessels and osteoprogenitors 
(Shapiro 2008). This anatomical distinction exemplifies the development of two different kinds of cartilage by 
MSCs: (1) persistent and stable cartilage at the joint site and (2) transient cartilaginous models elsewhere 
that will accomplish endochondral ossification (Pelttari,  Steck, and Richter 2008).
As bones enlarge further, so-called secondary ossification centers are established, in the epiphyses of the 
newly formed bone by the same processes occurring for the first ossification centre. Growth plate chondro-
cytes continue to proliferate between regions of bone of the primary and secondary ossification centers to 
allow bone elongation, a process that will stop at time of adolescence.  
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Figure 6 “Wnt and FGF signals interact to coordinate growth and cell fate specification during limb development. In the newly established limb 
bud, both Wnt and FGF proteins signal throughout the limb mesenchyme and maintain all cells in a multipotent, proliferative state ( region 
indicated by red/blue hatching). Following limb outgrowth, cells in the center of the limb are no longer within range of the signals. This allows 
cell cycle withdrawal and expression of Sox9, leading to establishment of the chondrogenic core (indicated in blue)”   (adapted figure and 
caption from ten Berge et al. 2008).
1.2 Focusing on molecular pathways 
Endochodral bone formation is influenced by morphogen crosstalks among different cell types. The list of 
signalling factors affecting growth plate development is long and not fully characterized from the molecular 
stand point. Cytokines, growth hormone, retinoids, thyroid hormone, oestrogen, androgen, vitamin D and 
glucocorticoids among others, exert important roles during embriological development and postnatal 
remodelling (Kronenberg 2003). 
In the developing limb bud, the influence of FGF and Wnt signals from the surrounding tissue firstly main-
tains mesenchymal cells in an undifferentiated proliferative state and thus coordinates tissue growth and cell 
fate determination (Ten Berge et al 2008; Figure 6). 
At condensation stage, progenitors are at least bipotential with 
regard to their final cell fate determination (Day and Yang 2008). 
Infact, during intra-membranous ossification, Wnt signaling is 
high and inhibits chondrocyte differentiation while promoting 
osteoblast differentiation. On the contrary, in endochondral ossi-
fication, Wnt signaling is kept low such that only chondrocytes 
can differentiate; similarly, Wnt signaling will be upregulated at 
the perichondrium where osteoblasts will differentiate. Up-
regulation of SOX9, SRY (sex determining region Y)-box 9, the 
main gene driving chondrocyte differentiation, occurs when 
cells in the center of the limb are no longer within the range of 
FGF and Wnt signals: the diminishing of the influence of the 
morphogens reflects the establishment of the chondrogenic 
condensed core (Horton and Degnin 2009). Cellular communi-
cation at this stage gets more complicated by the expression of 
further molecules such as Sonic Hedgehog (SHH) and BMP2 
that play as important regulators of limb outgrowth.
Once the growth plate is established, maturing chondrocytes 
produce the signaling factor Indian Hedgehog (Ihh), a soluble 
molecule of the Hh family which exerts important roles in regu-
lating proliferation, maturation rates, and ossification processes. 
Ihh promotes the expression of BMPs that, in turn, contribute to cartilage and bone formation by (i) up-
regulating chondrocyte proliferation, (ii) increasing the length of proliferating columns of chondrocytes and 
(iii) converting perichondral cells into osteoblasts. 
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Figure 7  “Interactions between proliferating and pre-
hypertrophic chondrocytes in the growth plate. In 
response to Ihh signaling, PTHrP is secreted by the 
proliferating chondrocytes, reaches the prehypertrophic 
chondrocytes, and retards their progression to the 
hypertrophic state, thereby delaying column elongation 
and synchronizing it with cell differentiation and other 
processes taking place in parallel, such as secretion and 
organization of the extracellular matrix, which is needed 
for columnar structural integrity. In addition, Ihh regulates 
the expression of BMP genes, which also upregulate 
chondrocyte proliferation. BMP, bone morphogenetic 
protein; P, proliferation; D, differentiation” (from Lenas, 
Moos and Luyten 2009).
Overall, BMPs antagonize the effects of FGF signalling (namely, shortening proliferative columns both by 
decreasing chondrocyte proliferation directly and by suppressing Ihh expression) at the site of proliferative 
(P) and terminal differentiated (D) chondrocytes (Figure 7) (Lenas, Moos, and Luyten 2009; Kronenberg 
2003). 
Interestingly, Ihh and BMPs seem to be essential at the point of divergence between persistent cartilaginous 
tissues (Meckel’s cartilage of the mandible, nasal, ear, and intervertebral cartilages) and replacement ones 
that continue along the endochondral route in appendicular and axial skeleton. If chondrocytes lack expres-
sion of the pre-hyperthrophic markers (Ihh and BMP6), they fail to undergo hyperthrophy and consequently 
endochondral differentiation (Eames, de la Fuente and Helms 2003; Day and Yang 2008).
Moreover, in response to Ihh signaling, Parathormone (PTHrP) is secreted by proliferating chondrocytes at 
the end of the growth plate and by perichondral cells. This paracrine factor is a key player in the dialogue 
between cartilage and perichondrium. It primarily acts to maintain the proliferative pool of chondrocytes by 
feedback loop interplay with Ihh and it delays hyperthropy in prehypertrophic chondrocytes, in order to syn-
chronize it with cell differentiation and ECM secretion and organization (Kronenberg 2003; Lenas, Moos, and 
Luyten 2009 part II) (Figure 7). The aforementioned signaling pathways interact in a spatio-temporally 
coordinated fashion and are fundamental regulators for limb development. 
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Figure 8 Schematic of a section through an intact long bone and fracture healing stages. (a) inflammation: hematoma formation at the 
fracture gap and development of initial callus formed by mesenchymal cells; (b) callus differentiation: formation of chondrous tissue adjacent 
to the fracture and intramembranous ossification adjacent to the bone and distal to the fracture; (c) ossification: replacement of cartilaginous 
callus by osseous tissue via endochondral ossification, and (d) remodeling: restoration of original bone geometry (from Bailon-plaza and 
Van Der Meulen 2001)
2. Repair capacity of skeletal tissue
2.1 …at the bone side…
Unlike other adult tissues, bone skeleton possess a unique capacity to heal after fracture, loss or damage 
by forming new bony tissue that is undistinguishable from adjacent injured parts and without leaving a scar. 
This innate reparative and regenerative capacity of bone shares many features with development 
(Sundelacruz and Kaplan 2009). For example in both processes, 1) condensation and differentiation into 
cartilage-bone tissues occur with fetal and adult skeletal progenitors, 2) molecular markers of chondrogene-
sis and osteogenesis that regulate cell differentiation are conserved, 3) ECM remodeling and vascular inva-
sion are strongly required (Colnot et al. 2003). Moreover, injured skeletal elements use cells of their own 
embryonic origin for repair (Leutch, et al. 2008; Gerstenfeld, et al. 2003). In case of bone fracture, structural 
and functional features must be re-established by creating morphogenetic fields and instructive cross talks 
between adjacent tissues, in analogy with specific bone development paths. Obviously, remarkable differ-
ences between development and repair process can be also identified: for instance mechanical forces and 
inflammation play important role in the latter, whereas they are not involved during development (Figure 8).
For example, after a fracture is sustained in a long bone structure, inflammatory response takes place with 
recruitment of macrophages and polymorphonuclear cells: an initial hematoma (Figure 8a) is formed under 
the control of several inflammatory factors. Soft callus with granulation tissue develops thanks to proliferative 
fibroblastic cells. When BMPs start to be produced, osteoprogenitors are induced to differentiate firstly into 
chondrocytes and then into osteoblasts following the endochondral route. Intramembranous ossification oc-
curs only adjacent to reminiscent bony structures and distal to the fracture (Figure 8 b-c-d) 
Therefore, molecular and cellular insights concerning intramembranous and endochondral bone formation 
not only offer deeper knowledge in developmental system biology but also contribute in understanding 
spontaneous healing processes of damaged or diseased bone and, thus, may also inform bioengineering 
strategies (Zelzer and Olsen 2003). 
2.2 …at the cartilage side…
When a degenerative or traumatic injury occurs at the site of articular cartilage, unlikely what happens in 
bone lesions, the innate reparative capacity results in suboptimal and inefficient tissue recovery. 
The avascular nature of the cartilage remarkably impairs the healing process because of the delay in re-
cruitment of progenitors. 
Nevertheless, the skeletal system tempts to reply to the injury by stimulating mesenchymal progenitor cells 
from the underlying subchondral bone and by relying on their capacity to undergo chondrogenic differentia-
tion. This potential, unfortunately, can turn into a limitation: MSC-derived chondrocytes undergo premature 
hypertrophy and develop into a transient, endochondral cartilage, instead of stable, articular cartilage-like 
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tissue in line with the developmental endochondral pathway they recapitulate.
Thus, repair of articular defects with stable reparative tissue represents an open clinical challenge. 
3. Skeletal defects: reparative and regenerative clinical strategies
In case of critically sized skeletal defects caused by post-traumatic tissue loss, benign or malignant tumors, 
atrophic nonunions, periprosthetic bone loss, arthrodesis, and degenerative diseases, spontaneous healing 
can not support tissutal and functional recovery. In the following paragraphs, an overview of current surgical 
procedures will be given.  Moreover, tissue engineering and cell-based therapy concepts will be described 
as interesting alternatives to these conventional clinical approaches for skeletal regeneration. 
3.1 Conventional techniques 
3.1.1	
  …for	
  bone	
  defects…
Skeletal defects requiring bone-graft repair procedures are estimated in 1 million clinical cases a year. 
Worldwide, socioeconomic consequences of such treatments represent a major concern, and will increase 
in the next years due the aging of their population. Current surgical procedures consist in autologous bone 
grafts, autogenous bone grafts or metallic and ceramic implants (Salgado, et al. 2004).
Autologous bone graft, that is bone taken from another site of the patient’s own body, has been the gold 
standard of bone replacement for many years because it provides osteogenic cells as well as essential os-
teoinductive factors needed for bone healing and regeneration. Usually trabecular bone from the patient’s 
iliac crest is taken, but cortical bone can be used as well. HIgh percentages of success are reached but 
limited amount of the autograft that can be obtained due to donor site morbidity.
Allograft, bone taken from somebody else’s body, could be an alternative. However, the engraftment has 
lower chances than with the autograft due to immune rejections and pathogen transmission, that might be 
introduced.
As an alternative to these two bone grafts, there are metallic and ceramic prostheses to be implanted at the 
defect site. Metals, although providing immediate mechanical support at the site of the defect, exhibit corro-
sion, poor overall integration with the tissue at the implantation site, and may lead to surrounding bone re-
sorption. Ceramics (e.g. bioglasses and calcium phosphates), on the other hand, show osteoconductivity 
and osteoinductivity but are brittle and not degradable (Salgado, et al. 2004).
3.1.2	
  …for	
  cartilage	
  defects…
For chondral or osteochondral lesions, the ultimate clinical strategy is total replacement of the joint with me-
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tallic prostheses. Nevertheless, according to the severity and the extension of the defects, some alternative 
treatment options can be taken into account. Marrow-stimulating techniques (e.g., microfracture or sub-
chondral drilling of the bone) recall the principle of inducing invasion of mesenchymal progenitor cells from 
the underlying subchondral bone and promote the initiation of cartilage repair by chondrogenic differentia-
tion of MSC. Unfortunately, the outcome of these procedures is highly variable and often results in fibro-
cartilaginous repair tissue, with limitations in quality and function as compared to native hyaline tissue. Mo-
saicplasty techniques exploit the possibility to harvest punches of autologous cartilage from non-bearing 
areas and to re-implant them in the damaged site. Obviously, also in this case, donor site morbidity and infe-
rior repair tissue limit the clinical outcome (Pelttari, Steck, and Richter 2008). 
3.2 Tissue engineering approach
In the last decades, new options in the field of regenerative medicine have been achieved thanks to the abil-
ity in tailoring and controlling in vitro fabrication of living replacement devices to ultimately restore in vivo 
tissue function (Vacanti and Langer 1993). 
Researchers have been reaching this goal by combining the knowledge from physics, chemistry, engineer-
ing, materials science, biology, and medicine in an integrated manner, enclosed in the concept of Tissue 
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Figure 9 Schematic of conventional Tissue Engineering paradigm: 1) harvesting of tissue biopsy and isolation of regenerative cells; 2) cell 
seeding on monolayer surfaces (e.g. petri dishes, flasks); 3) cell expansion in monolayer till sufficient cell number is reached; 4) cell seeding 
into 3D scaffolds and maturation of the construct (cells and scaffold) in vitro; 5) complete generation of the graft and (6) implantation into 
the defect site 
Engineering. Cells, scaffold and differentiating signals are the three key players for tissue engineering appli-
cation and, although they could work individually, their combination might be beneficial for clinical applica-
tions. 
Thus, nowadays, clinically relevant pre-formed tissue replacements, as well as ex-vivo human tissues serv-
ing as model systems, could be engineered (Sundelacruz and Kaplan 2009). 
Ex vivo skeletal tissue manufacturing usually begins with cell harvesting from donor biopsy. Cells of interest 
are isolated (Figure 9 - step 1), usually plated in conventional monolayer expansion system (i.e. plates, 
flasks) (Figure 9 - step 2), and expanded until sufficient cell number is reached (Figure 9 - step 3). Then 
cells are collected and seeded either by gravity or by dynamic methods (e.g. centrifugation, spinner flasks, 
perfusion bioreactors) throughout 3D biomaterials (Figure 9 - step 4), that play as (i) cell carriers (ii) me-
chanical supports and (iii) informative biological cues. The graft generated could be further developed in 
vitro or directly re-implanted in vivo (Figure 9-steps 5 and 6).
Notably, as far as cell source is concerned, both developmental and regenerative skeletal formation proc-
esses are mediated by mesenchymal stem and progenitor cells. 
Adult mesenchymal stem cells (MSC) have become the main source of choice for skeletal tissue engineer-
ing approaches as they meet several requirements for clinical applications such as (i) lower site morbidity 
for harvesting, (ii) good numerical yield upon in vitro expansion culture, (iii) broader differentiation capacity 
in comparison with differentiated primary cells (i.e. chondrocytes and osteoblasts). 
Embryonic stem cells (ESCs) and the more recently developed iPS cells (induced pluripotent stem cells) are 
the most appealing cell source in terms 
of pluripotency. However, many factors 
have limited their application to human 
cell therapy, including ethical concerns, 
immunological incompatibilities, safety 
issue, potential for malignant tumor 
growth, heterogeneous differentiation, 
and an insufficient understanding and 
control of differentiation. For these rea-
sons, adult MSCs are more clinically 
compliant for the current medical appli-
cations: MSC have the ability to gener-
ate skeletal tissue in a variety of ex-
perimental models, and hold great po-
tential in cell based approaches for 
regenerative medicine (Sundelacruz 
and Kaplan 2009).	
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Figure 10 Bone tissue engineering : example of implementation of conventional 
paradigm by performing cell selection, cell seeding and cell expansion directly 
throughout 3D scaffolds (results taken from Braccini et al. 2005)
3.2.1	
  Bone	
  tissue	
  engineering
In the context of bone tissue engineering, thus far human adult MSC (e.g from bone marrow or adipose tis-
sue) have been shown to generate bone exclusively through direct osteogenic differentiation (i.e., in a man-
ner akin to intramembranous ossification), using a mineralized surface as “priming” substrate and, possibly, 
a boost of differentiating growth factors such as BMP2 (Axelrad and Einhorn 2009). 
Different attempts in introducing novel paradigms have been made: it has previously been shown that adult 
MSC derived from bone marrow aspirate (Braccini, et al. 2005) (Figure 11) or lipoaspirate (Scherberich, et 
al. 2007) can be extensively expanded by loading and culturing freshly isolated cells directly within the 
pores of a 3D scaffold, ultimately generating an engineered construct in a simple streamlined process which 
completely bypasses the phase of monolayer expansion.  
Despite encouraging in vitro results and few first clinical trials, the cost-benefit and the efficacy of bone tis-
sue engineering approaches have still to 
be demonstrated. In fact, cell survival 
upon graft implantation still remains an 
unsolved issue, mainly for the lack of 
efficient coupling between vasculogenic 
and osteogenic potential, and thus, im-
pairs the clinical outcome of tissue engi-
neering approach.
3.2.2	
  Cartilage	
  tissue	
  engineering
As a breakthrough in the field of carti-
lage regeneration, in 1994 Brittberg and 
colleagues introduced a new procedure, 
so called Autologous Chondrocyte 
Transplantation (ACT). The patient un-
dergoes two joint surgeries: the first to 
harvest a cartilage biopsy from which 
autologous chondrocytes can be isolated 
and the second to re-implant the autolo-
gous chondrocyte graft to repair the de-
fect. This cell-based method relies on (i) in vitro expansion of autologous chondrocytes prior to injection at 
the defect site as a cell suspension or—in an improved version—in association with a supportive matrix 
(matrix-assisted ACT, MACT) and on (ii) chondrocyte capacity to reconstitute the native matrix once back in 
vivo (Brittberg 1999; Pelltari, Winxmerten, and Martin 2009). The clinical outcome of these chondrocyte-
based techniques is generally good, as they lead to decreasing of symptoms for the patient but in many 
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Figure 11Cartilage tissue engineering: exemplification of modularity of tissue 
development and requirement of pre-cultivation of the graft to achieve a certain 
degree of maturation (results taken from Moretti et al 2005 ) 
cases results in the formation of inferior fibrous repair tissue in terms of mechanical properties and durability.
Different aspects of this clinical procedure have been implemented in the recent years. On one side, it has
been questioned whether in vitro maturation of the graft is required (Moretti, et al. 2005 and figure 11) by 
formulating the question “how good is good enough?” in terms of product quality and clinical outcome. In-
deed, chondrogenic pre-cultivation is key to (i) improve donor cell retention, (ii) possibly protect cells from 
inflammatory reaction at the repair site, (iii) enhance in vivo development, (iv) improve cellular response to 
mechanical loading and, (v) from the clinical point of view, guarantee easier surgical handling and possibly 
earlier postoperative loading (Pelttari, Wixmerten, and Martin 2009). 
On the other side, product manufacturing pipeline could be improved, simplified and streamlined: a remark-
able example of single closed system for graft production is the device ACTES (Autologous Clinical Tissue 
Engineering System) currently under development by Octane, which is an automated bioreactor where 
autologous cartilage biopsy can be digested and isolated chondrocytes can be expanded before being 
seeded and cultured on an osteochondral porous scaffold prior to implantation.  
3.2.3	
  Bioreactors	
  in	
  tissue	
  engineering
Conventional tissue engineering pipelines are costly, labor-intensive and time consuming, due to their man-
ual nature. Successful clinical use of engineered tissue products, as well as their commercial exploitation, 
might be critically dependent on the introduction of bioreactors. Bioreactors, intended as a means to gener-
ate and maintain controlled physicochemical culture environment, indeed represent  key elements in devel-
oping automated, standardized, traceable, cost-effective, safe and regulatory-compliant manufacture of 
cell-based products or engineered grafts for clinical applications (Martin, Smith, and Wendt 2010).
Implementation of traditional tissue engineering paradigms passes through better control and standardiza-
tion: this can be achieved, firstly, with automation of culture procedures by means of bioreactor systems. 
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Figure 12 Examples of implementation of conventional tissue engineering paradigm by means of bioreactor systems. a) Bioreactors 
as tool to perform streamlined cell seeding and cell culture directly in 3D scaffold and within a single closed system. b) Bioreactor 
applied in intra-operative procedure and exploited to perform cell treatment directly prior to graft implantation. 
Bioreactors, for instance perfusion bioreactors, are meant  (i) to improve seeding and culture conditions of 
engineered constructs by  enhancing mass transfer, (ii) to control and monitor critical culture parameters, 
(iii) to provide physical conditioning of developing tissues and (iv) to predict graft mechanical functionality.
Unlike conventional manual based procedures, bioreactors allow automation and streamlining of in vitro cul-
ture as depicted in Figure 12a, and up-scaling of graft and production for efficient clinical translation. In con-
trolled closed bioreactor system, computational fluid dynamics can be applied to describe flow dependent 
processes as  model-based simulations of velocity and shear stress profiles. This, in turn, could be funda-
mental to understand and optimise operating parameters and to predict culture outcome. Bioreactor based 
cultures might become robust 3D model systems, where external perturbations of culture parameters can 
be predicted and tuned to maintain system stability (Wendt, et al. 2009). 
Moreover, the conventional tissue engineering paradigm we described could be further adjusted towards an 
intra-operative vision, if feasible. In this latter case, bioreactors could implement cell preparation step (i.e. 
biopsy treatment, cell isolation, combination with carrier) directly upon graft implantation (Figure 12b steps 
1,2,3).
3.3 Developmental engineering concept
Nowadays, to the extent that the mechanisms of tissue development and repair are known, tissue engineer-
ing could undergo a major conceptual and methodological transformation: a change in the mindset of tissue 
engineers might move experiments from trial-and-error approaches to rigorous plans for regenerative medi-
cine (Lenas, Moos, and Luyten 2009 part I and II). 
In principle, the new paradigm in tissue engineering is no longer three-dimensional (3D) cell growth and dif-
ferentiation but strict biomimetism, so that in vitro processes recapitulate key events of in vivo development 
and repair courses. 
This strategy will allow fundamental understanding of what makes a tissue different than a 3D cellular graft 
and develop a methodology that can meet cost-effective, quality-validated, and clinically oriented process. 
In particular, substantial pieces of information on spatial-temporal organization of developing tissues and 
functions could be keys for graft manufacturing implementation. 
As a matter of fact, the benefits of recapitulating complicated developmental stages in in vitro procedures 
might not be immediately captured: the process design point of view should be taken. The knowledge 
gained from developmental biology that can be incorporated into tissue engineering procedures can be 
summarized in (i) path-dependence of the steps, (ii) robustness of the system, (iii) modularity of the process, 
and (iv) semi-autonomy of intermediate tissue forms. For example, in the growth plate, tissue size and cell 
differentiation progression takes place in a well-orchestrated manner: each developmental step represents 
an independent  module of the process which is robust and self established thanks to the tight 
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interconnection with previous and following steps. 
The nature of the process directly allows for cell and functional organization. Cartilage and bone tissue en-
gineering could be well adapted to this strategy and would potentially gain great benefits.  Engineered graft 
production could incorporate the critical steps occurring in vivo, acquiring stability, reproducibility and con-
trollability. The translation towards the so-called “developmental engineering” approach might pave the way 
to new generation graft manufacture (Lenas, Moos, and Luyten 2009 part I and II).
4. Experimental work
In the last years, different fields of investigation have risen from the initial concept of tissue engineering 
coined by Vacanti and Langer (Vacanti and Langer 1993). In our experimental work, we tried to merge to-
gether developmental engineering and bioreactor based approaches towards skeletal graft manufacturing 
implementation.
Firstly, we aimed to recapitulate embryological events occurring during endochondral bone formation to ul-
timately engineer bone grafts. We based our first hypothesis on the phenotypical instability of MSC when 
committed towards the chondrogenic lineage. As first demonstrated by Pelttari et al (Pelttari, et al. 2006), in 
vitro chondrogenesis of MSC leads to hyperthrophy, as direct consequence of initiation of endochondral 
route: this differentiation state is undesirable for cartilage tissue engineering purposes, where stability of 
formed cartilaginous tissue is mandatory for successful construct engraftment. On the contrary, the hyper-
throphic state of MSC could be exploited for bone tissue engineering: thus, by analogy to embryonic limb 
development, we first hypothesized that adult human bone marrow derived MSC, a clinically compliant cell 
source, were able to recapitulate the steps of endochondral route (condensation, chondrogenesis, hyper-
throphy, vasculogenesis coupled with tissue remodeling, and ultimately bone formation). Most importantly, 
this process could generate advanced grafts for bone regeneration by invoking a “developmental engineer-
ing” paradigm  and provide a valid model to study mechanisms governing bone development (Chapter I). 
We thus aimed at efficiently transferring the paradigm to a bioreactor-based approach, by exploiting modu-
larity of endochondral pathway and semiautonomy of intermediate tissues. Each developmental milestone 
could be translated in specific controlled bioreactor in vitro phases, possibly up-scaling graft manufacturing 
and production. Therefore in the second part of the thesis, we focused on streamlining the process, focus-
ing on the first two events of endochondral route (i.e. condensation and chondrogenesis) and by means of a 
single closed bioreactor system. We first aimed at optimizing the development of cartilaginous graft by cell 
seeding, proliferation, condensation and chondrogenic differentiation directly in 3D scaffolds and by apply-
ing temporally defined and controlled perfusion regimes. Secondly we aimed at assessing the feasibility of 
up-scaling graft size, in the clinical context of unicompartimental joint cartilage repair (Chapter II). 
Finally, we wanted to achieve robustness of each module of the endochondral route and we started from the 
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first step: we set a model system to study and specifically control initial cell condensation, directly in 3D 
porous scaffold within perfusion bioreactor system. It has been previously demonstrated how important is 
cell distribution upon scaffold seeding for subsequent tissue maturation (Wendt, et al. 2006) and it has been 
studied the importance of cell density to prime chondrogenesis (Moretti, et al. 2005). We combined different 
complementary experimental approaches (biomaterial design, computational fluid dynamics and bioreactor 
based cell culture) and established a model system to study the correlation between changes in scaffold 
porosity, shear stress and cell distribution upon perfusion seeding. By smart scaffold design and proper 
perfusion regime we controlled cell distribution, with the ultimate goal to obtain the desirable cell density 
supporting proliferation or differentiation, in accordance to the developmental stage we aimed to recapitu-
late (Chapter III). 
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Recapitulation of the Aims of the experimental work:
Chapter I: Recapitulation of embryological events that occur during endochondral bone formation to ulti-
mately engineer bone constructs
Chapter II: Streamlining the first events of the endochondral route; Optimization of cartilaginous graft devel-
opment by cell seeding, cell proliferation and chondrogenic differentiation directly in 3D scaffolds and within 
a single closed bioreactor system; Upscaling graft size for cartilage repair
Chapter III: Control of initial cell distribution in 3D matrices upon perfusion bioreactor seeding and therefore 
control of cell condensation phase in the context of endochondral graft manufacturing. 
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Abstract
In the context of developmental t issue engineer ing for skeletal regenerat ion, we aim at 
recapitulat ing, opt imizing and streamlining the f i rst events of endochondral route 
(namely condensat ion and chondrogenesis) , by combining speci f ic s ignal ing cues with 
3D scaffold cul ture and bioreactor based approach. This protocol could be adapted both 
for endochondral and for car t i lage t issue engineer ing. Therefore, as logical star t ing 
point , we hypothesized a cl in ical scenar io for chondral graf t generat ion, by using 
cl in ical ly relevant cel l densi t ies. Human ar t icular chondrocyte (HAC) were isolated, 
eff ic ient ly expanded t i l l chondrogenic permissive cel l densi ty was reached and fur ther 
induced towards chondrogenic di fferent iat ion to deposi t extracel lu lar matr ix r ich in 
gl icosamminogl icans (GAG) and col lagen type I I . Al l these steps where per formed 
throughout 3D hyaluronan based meshes (Hyaff-11) and direct ly in the bioreactor 
system. Ul t imately, we conf i rmed the feasibi l i ty of th is approach with cl in ical ly s ized 
constructs, by graf t and bioreactor upscal ing. Moreover, fur ther developmental capacity 
of the generated graf t was chal lenged in ectopic implants, demonstrat ing the impor tance 
of in v i t ro precul t ivat ion for graf t stabi l i ty. In comparison with convent ional t issue 
engineer ing techniques rely ing on monolayer cel l expansion (e.g. , f lask or petr i dishes) 
and 3D construct cul ture in stat ic condit ions, bioreactor based cul tures offer ( i ) 
comparable product qual i ty, ( i i ) streaml ined process so that less intensive manual labor 
and ( i i i ) graf t upscal ing. Thus, the paradigm we introduced represents a remarkable step 
forward to t ranslate engineered products  and developmental engineer ing concept f rom 
bench to bedside.
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Introduction
The novel trend of regenerative medicine is the recapitulation of the events occurring during tissue devel-
opment along ex vivo manufacturing process. In line with this “developmental engineering paradigm”, skele-
tal regeneration could undergo a major conceptual change: the generation of skeletal grafts might be im-
plemented by mimicking the physiological steps of tissue formation, so that endochondral route (Lenas , 
Moos  and Leutch 2009, I).  
Therefore, the pipeline towards skeletal graft might pass through cell condensation by proliferation, chon-
drogenic differentiation, hyperthrophy, vascular ingrowth combined with matrix remodelling and, at last, 
bone formation. 
The logical starting point for the implementation of this approach is the optimization and the streamlining of 
the first two events of this route (i.e. proliferation and chondrogenic differentiation). 
As a matter of fact, the modularity of the process allows to translate this paradigm to cartilage graft manu-
facturing, an open clinical challenge where developmental engineering paradigm may be beneficial. 
Lesions of articular joint surface might result in end-stage osteoarthritis and often require surgical interven-
tions and total joint replacement by prosthesis. Modern tissue engineering approaches might offer an alter-
native paradigm for repair and regeneration of joint surface defects, in terms of clinical product and surgical 
procedures. 
The conventional tissue engineering strategy to generate cartilage grafts typically relies on extensive in vitro 
monolayer proliferation (e.g., on flasks or Petri dishes) of the small number of cells that can be obtained from 
a typical sized biopsy, prior to cultivation within three dimensional (3D) scaffolds. Method associated with 
monolayer cell expansion and static culture of the graft are performed by specialised technicians, by using 
manual bench-top cell culture techniques. Although well established, these techniques (i) are labor-
intensive, (ii) require specialised Good Manufacturing Practice (GMP) facilities, (iii) possess inherent safety 
risks, (iv) are challenged by intra-/inter-operator variability, and (v) have pragmatic limits on increasing unit 
production volumes (up-scaling), due to the manual nature of the procedures (Martin, Smith and Wendt 
2009). A manufacturing process that bypasses the phase of monolayer cell expansion and static culture has 
the potential to generate engineered grafts with a more simplified and streamlined procedure, facilitating 
process automation within a single closed system. 
In the context of bone regeneration, it has previously been shown that mesenchymal cells derived from a 
bone marrow aspirate (Braccini et al., 2005) or lipoaspirate (Scherberich et al., 2007) can be extensively 
expanded by loading the freshly isolated cells directly into a perfusion bioreactor and culturing the cells 
within the pores of a 3D scaffold, ultimately generating an engineered construct in a simple streamlined 
process which completely bypasses the phase of monolayer expansion. 
In this work, we describe the adoption of the streamlined tissue engineering paradigm to produce cartilage 
grafts for small and large-scale cartilage defects and ultimately to recapitulate the first events of endochon-
dral route. We specifically aim at simplifying conventional cell and tissue culture methods by using
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bioreactor-based approach and at investigating cell proliferation and chondrogenic differentiation, directly 
within a three-dimensional biomaterial. We hypothesise to maintain the chondrogenic potential of human 
articular chondrocytes (HAC) - chosen as default cell source for cartilage tissue engineering- upon prolifera-
tion in 3D perfused scaffold (Hyaff-11 meshes), by switching the cellular phenotype with limited culture con-
dition arrangements within a single closed bioreactor system. 
Materials and methods
Car$lage	
  Isola$on:
Human articular cartilage samples were collected post mortem (within 24 hours after death), with informed 
consent and in accordance with the local Ethical Commission, from the knee joints of 8 individuals  (mean 
age 63±5 years), with no history and no radiographic signs of joint disease. Human Articular Chondrocytes 
(HAC) were isolated using 0.15% type II collagenase for 22 hours and resuspended in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% fetal bovine serum, 4.5 mg/ml D-Glucose, 0.1mM nonessential 
amino acids, 1mM sodium pyruvate, 100nM HEPES buffer, 100U/ml penicillin, 100ug/nl streptomycin, and 
0.29mg/ml L-Glutamine (Complete Medium). Primary HAC were counted (average 2.92±0.12 E+06 cells/
grams of biopsy) and directly used for the following experimental groups. 
HAC	
  Prolifera$on	
  Phase:
Clinically applicable cell seeding densities were calculated based on data including an average size of a 
cartilage biopsy (up to 500 mg) (Brittberg, et al. 1994), the number of chondrocytes that can be obtained 
from a cartilage digest (2.5E+06 cells/gram cartilage) (Jakob, et al. 2003), and the dimensions of the clini-
cally available engineered cartilage grafts based on hyaluronan acid: 1) Hyalograft-C® (2cm x 2cm x 
0.2cm), usually used in the repair of small defects; and 2) larger scaffolds (5cm in diameter x 0.3cm), for 
large defect site (above 10cm2). Hyaff-11 meshes were either previously coated with fibronectin (concentra-
tion 50µg/ml), or remained uncoated to serve as controls.
In four independent experiments aiming at simulating the first clinical scenario (small graft generation), 
1E+05 HAC were perfusion seeded onto 0.6cm in diameter x 0.2cm thick Hyaff-11® non-woven meshes 
(Fidia Advanced Biopolymers, FAB, Italy) at the clinically applicable cell density of 1.6E+06 cells/cm3 scaf-
fold volume, for 16 hours, at a perfusion rate of 1mm/s within a 10%CO2/19%O2 incubator. Following seed-
ing, constructs remained in the bioreactor system (Wendt, et al. 2006) and were perfused at 100µm/s for an 
additional two weeks with “proliferating” culture medium (Complete Medium supplemented with 1ng/ml TGF 
ß1 and 5ng/ml FGF-2). 
In other four independent experiments designed to validate the large scaffold manufacturing process, 
1E+06 HAC were perfusion seeded and expanded onto 5cm in diameter x 0.3cm thick Hyaff-11® non-woven
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meshes at the clinically applicable cell density of 1.6E+05 cells/cm3 scaffold volume in an up-scaled biore-
actor system as previously described (Santoro, et al. 2010). Engineered constructs after proliferation phase 
were harvested for molecular biology, biochemistry, histological and immunohistochemical analyses.
Primary freshly isolated HAC were seeded at 5000 cells/cm2 in conventional 2D culture flasks and expanded 
in monolayer as control for 3D expanded cells directly in bioreactors (Figure 1). 
HAC	
  Chondrogenic	
  Differen$a$on	
  Phase	
  Upon	
  Prolifera$on: 
Following two weeks of perfusion culture under proliferating cultivation conditions, the oxygen level of the 
incubator was reduced from 19% to 5%O2 to better support chondrocyte re-differentiation (Stroebel, et al. 
2010), and constructs were perfused with “differentiating” culture medium (Complete Medium supple-
mented with 10ng/ml TGFß1, 1UI/ml insulin, and 0.1mM ascorbic acid 2-phosphate) (Moretti, et al. 2005) for 
an additional two weeks. Monolayer expanded HAC underwent two passages along the 2 weeks of expan-
sion culture and at the end of culture time were statically seeded onto 0.6cm in diameter x 0.2cm thick 
Hyaff-11® at the same cell density than the one reached by the cells cultivated in the bioreactor system: dif-
ferentiation culture was performed at 5%O2 with “differentiating” culture medium in static conditions (Figure 
1). 
Constructs after chondrogenic differentiation phase were harvested for molecular biology, biochemistry, me-
chanical and histological and immunohistochemical analyses.
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Figure 1 Tissue engineering paradigms for cartilage graft generation. Conventional approach implies intensive manual labor procedures 
such as cell expansion on 2D plastic surfaces, cell seeding on 3D scaffolds and graft maturation under static conditions. Bioreactor 
based graft production aims at streamlining the process by performing cell seeding, cell proliferation and chondrogenic differentiation 
directly into 3D scaffolds and within a single closed system.    . 
In	
  vivo	
  evalua$on	
  of	
  construct	
  development:
Constructs upon bioreactor culture (either after proliferation or differentiation phases) were implanted subcu-
taneously in nude mice and harvested respectively after either 6 and 8 weeks or after 8 weeks, in order to 
compare total culture time and total in vivo development. Constructs were analyzed for histology as fol-
lowed.
Histological	
  and	
  immunohistochemical	
  analyses:
Constructs were fixed in PFA 4%, embedded in paraffin and further analyzed histologically and immunohis-
tochemically. Safranin-O staining was done to visualize glicosamminoglycans (GAG) distribution and colla-
gen type II immunostaining was performed as previously described (Candrian,et al. 2008). Immunohisto-
chemistry for Ki67 (AbCam) was performed as suggested by the manufacturer’s instructions and counter-
stained with alcian blue/immunofluorescence.
Mechanical	
  tests:
Independent samples were also assessed biomechanically by indentation tests as previously described 
(Santoro, et al. 2010).
Biochemical	
  analyses:
Constructs were biochemically analyzed to quantify GAG content by means of 1,9-dimethylmethylene blue 
assay and to assess the number of cells present per sample (CyQUANT® Cell Proliferation Assay Kit) as 
previously described (Candrian, et al. 2008). 
Molecular	
  biology	
  analysis:
RNA extraction, cDNA preparation and RT-PCR were performed from the samples as previously described 
(Candrian, et al. 2008). 18s was used as housekeeping gene to normalize the expression of the genes of 
interest, namely collagen type I (COLL I), collagen type II (COLL II), Sox-9 (Applied Biosystems), Ki-67 
(Applied Biosystems).
Sta$s$cal	
  analysis:
Data are presented as mean value +/- SD. t-test or non-parametric test (Mann-Whitney) were performed 
after checking normal distribution of the values (significant p-value < 0.05 or 0.001).
Results 
Firstly we assessed HAC streamlined culture within 3D hyaluronan meshes, with the ultimate goal to engi-
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neer cartilage grafts based on conditions relevant for  Hyalograft-C production. We compared this  novel 
bioreactor-based paradigm with the conventional cartilage tissue engineering approach (Figure 1): on one 
side, freshly isolated chondrocytes where expanded and further differentiate directly in 3D within a closed 
bioreactor system; on the other, proliferation was performed in 2D in tissue flasks while matrix deposition 
was induced upon scaffold seeding according to the indications of current and conventional clinical appli-
cations. 
In the streamlined approach, HAC could be extensively expanded directly within Hyaff-11 meshes, coated 
or not coated with fibronectin. Chondrocytes expanded on fibronectin-coated Hyaff-11 proliferated to a 
greater extent than in uncoated scaffold controls during the initial time frame of the proliferation phase, and 
reached a plateau at day 14, while those of the control group proliferated slowly and steadily until reaching 
the same threshold at day 14 (data not shown). In particular (Figure 2A), seven days of 3D expansion di-
rectly within fibronectin coated Hyaff-11 meshes resulted in 3.9±0.6 cell doublings, and in 14 days reached 
4.7±0.6 doublings (corresponding to 2.7E+06 total cells per scaffold; or 4.8E+07 cells/cm3). This number 
could be referred to the data present in clinical reports reporting such cell density for scaffold seeding after 
monolayer expansion (Marcacci et al., 2007). 
As a matter of fact, in some donor cases the same desirable number of cell doublings could only be ob-
tained by prolonging the culture time 
until day 21 (data not shown): neverthe-
less, the delay in switching to differen-
tiation phase was experienced also in 
monolayer expanded cells, rising the 
problem of donor variability in prolifera-
tion capacity and the need of monitor 
and control  of these culture parame-
ters, that can be accomplished with 
bioreactor systems by means of oxy-
gen sensors, as recently implemented 
in our systems (Santoro et al., submit-
ted 2011).
As depicted in Figure 2C, the expres-
sion of the key marker for proliferation 
(Ki67) was detected via immunohisto-
chemistry demonstrating that freshly 
isolated HAC were able to re-enter the 
cell cycle upon the quiescence they 
experience in the native microenviron-
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Figure 2 Bioreactor based approach in the context of Hyalograft-C graft generation. A) 
Trend of total population doublings along proliferation (day7, day14) and differentiation 
(day 28) phases in 3D scaffolds. B) trend of GAG production expressed as percentage 
of total scaffold wet weight along proliferation and differentiation phases. C) 
Immunohistochemistry at  the end of proliferation phase (day 14) for proliferaitive marker 
Ki67 (red) with Alcian Blue as counterstaining (light blue). D) Safranin-O staining at the 
end of chondrogenic differentaition phase for GAG detection (red). Scale bar = 50um
ment.  Subsequent to 3D proliferation phase, when cultured under differentiating conditions for two weeks, 
HAC stopped to proliferate (additional 0.6 doublings) and began to redifferentiate. Constructs cultured un-
der this expansion/differentiation regime contained 0.25±0.05% GAG (Figure 2B) per wet weight and 
stained positive for Safranin-O staining (Figure 2D), similar to constructs generated in the same overall time 
frame by conventional manual culture processes (Candrian et al. 2008). 
Once assessed the feasibility of the procedure relevant for the clinical scenario and the graft size of 
Hyalograft-C, we verified whether the streamlined approach described above could be further extended and 
applied to the generation of larger-scale cartilage grafts for uni-compartmental resurfacing (i.e., 50mm di-
ameter x 4mm). The initial cell seeding 
number was determined by taking into ac-
count the same average biopsy size and 
digestion yield of the cartilage biopsy, but 
ultimately re-calculated to consider the 
larger graft dimensions, and thus, permitting 
a significantly lower cell seeding density 
(only 1.7E+05 cells/cm3). The primary chon-
drocytes could be seeded and extensively 
expanded within the Hyaff-11 meshes, and 
depending on the donor, underwent 4.5 
doublings in either 14 or 21 days, reaching 
cell densities of 8E+07 cells/cm3.  Interest-
ingly, HAC seeded at lower cell density continued to proliferate even after the switch towards the chondro-
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Figure 3 Gene expression analysis for HAC expanded in monolayer (2D) and 
directly throughout 3D scaffolds within the bioreactor system. Data are 
normalized versus housekeeping gene 18s (* p<0.05; **p<0.01). 
Figure 4 Safranin-O staining (A,B) and collagen type II immunostaining (C,D) for conventional (A,C) and streamlined (B,D) approaches
(Scale bar 200 um). Gene expression analysis for constructs generated with conventional and streamlined apporaches (E). Data are 
normalized versus housekeeping gene 18s (* p<0.05; **p<0.01).
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genic differentiation phase and they underwent further doublings in the last 2 weeks of the culture time. 
Along proliferation phase, we performed a broader gene expression profile analysis in order to better de-
scribe the differences between 2D and 3D expanded cells: the results indicate up-regulation of proliferative 
marker (Ki-67), matrix related protein (COLL II) and the chondrogenic related marker SOX-9 and down regu-
lation of COLL I compared to 2D expanded cells (Figure 3).
Upon chondrogenic differentiation phase, constructs were evaluated for matrix production by 3D expand-
edHAC: safranin-O staining (Figure 4B) was more pronounced as well as collagen type II expression (Figure 
4D) if streamlined production was performed as opposed to conventional technique (Figure 4A,C). These 
data were confirmed also by molecular biology analysis for matrix molecule expression (collagen type I and 
collagen type II) (Figure 4E) and by GAG quantification.
Importantly, mechanical properties of the constructs were determined by indentation tests: the compression 
stress was measured as 0.11±0.07 MPa, which corresponds to 1.5% of the loading bearing capacity of na-
tive cartilage. 
Finally, constructs were implanted subcutaneously in nude mice for 6-8 weeks in order to verify the stability 
and the quality of the engineered cartilage. Constructs processed in bioreactor units only for the 2 weeks 
(Figure 5A) did not rescue, during in vivo development, the production of matrix that was anticipated in the 
samples cultivated for further two weeks in bioreactor culture (Figure 5B). Importantly, engineered matrix 
obtained in vitro in these samples was stable upon in vivo incubation time., as depicted by the lack of mac-
roscopic signs of hyperthrophy.
Discussion
The approach we described merges two 
different cell culture processes (i.e., cell 
proliferation and chondrogenic differentia-
tion) directly in 3D scaffolds and within a 
single closed bioreactor unit, thus repre-
senting a significant step towards the de-
velopment of a simplified and streamlined 
manufacturing process for chondral and 
endochondral graft production.  
Bioreactor system has been introduced to 
specifically implement singular culture phases, namely cell seeding, cell proliferation and tissue develop-
ment; to decrease intensive manual procedures, thus risks of contamination and operator dependence vari-
ability, which are bottle necks factors for conventional labor techniques; and, additionally, to work as stand-
alone closed unit where graft generation could be totally performed (Wendt et al., 2009).
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Figure 5 Safranin-O staining for constructs precultiveted in vitro for two 
weeks (A) and 4 weeks (B) after in vivo culture (8weeks). (Scale bar 100um)
From the clinical standpoint, we have demonstrated the feasibility in dealing with clinically relevant seeding 
densities and we have validated the approach with critically sized grafts. This novel strategy might allow the 
application of tissue engineering paradigms to large cartilage defect repair, which still represents one of the 
major concerns for clinical use of engineered products. 
Starting from a low initial cell density, clinically relevant for the production of cartilage grafts in the size of 
FAB’s Hyalograft-C, primary human chondrocytes could be extensively expanded directly within the Hyaff-
11 meshes, reaching cell densities of 5E+07 cells/cm3. For comparison, in the established procedure to 
manufacture Hyalograft-C, 3D constructs are cultured following cell seeding with a minimum of 5E+06 cells/
cm3 chondrocytes, which have previously been expanded for 14-21 days by extensive 2D monolayer culture 
(Marcacci et al., 2007). Therefore, in the same timeframe, it would be feasible to achieve similar or even 
higher cell densities through the 3D expansion method as compared to 2D monolayer culture. 
Interestingly, while the scaffold coating did not appear to significantly increase the extent of proliferation (to-
tal cell doublings) at the two-week time point, fibronectin coating could potentially be used to increase the 
initial proliferation rate and ultimately reduce the time required for a proliferation phase.
When starting from an extremely low initial cell density, clinically relevant for the production of the large-
scale cartilage grafts, primary human chondrocytes could be still extensively expanded directly within the 
Hyaff-11 meshes, sufficiently reaching FAB’s current minimum cell density manufacturing specifications. 
Furthermore, 3D expansion showed to support cell proliferation while maintaining the chondrogenic poten-
tial. In fact, cells expressed higher level of Ki-67, SOX9, and COLLII compared to 2D expanded cells. These 
data confirmed how 3D environment could influence the degree of dedifferentiation, the lost of the chondro-
genic phenotype occurring when chondrocytes proliferate in monolayer. 
As far as chondrogenic differentiation is concerned, 3D expanded cells could switch phenotype and pro-
duce at increasing extent cartilaginous matrix rich in GAG and collagens, in comparison with samples 
treated with the conventional procedure.  
The bioreactor-based approach supported the generation of cartilaginous grafts, which were comparable in 
quality as those generated by long-established but labor intensive manual procedures (Candrian et al., 
2008). 
In vivo development of the constructs was followed for total of 8 weeks in ectopic mouse model: the boost 
with chondrogenic differentiation performed after proliferation phase resulted necessary to achieve good 
matrix deposition, thus stability and further maturation of the graft in vivo (Moretti et al., 2005). Interestingly, 
chondrocytes maintained the  chondrogenic phenotype without undergoing any hyperthrophy that typically 
would occur using MSCs primed towards chondrogenic differentiation.
The culture system we optimized might accomplish the clinical demand of simplified tissue engineering ap-
proaches for small and large cartilage defects and may help in better understanding scientific relevant 
questions, such as dedifferentiation, maturation and phenotypical stability of articular chondrocytes, as es-
sential events taking place during embryological limb developmental and cartilage-bone healing process. 
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Ultimately, the introduction of streamlined paradigm and development of GMP compliant bioreactor system 
might pave the way to the translation “bench to bed-side” for cartilage tissue engineering approaches (Mar-
tin, Smith and Wendt 2009).
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Chapter I I I
Model System To Control Cell Condensation Directly In 3D Scaffold In Bioreactor 
System 
“The	
   inAluence	
  of	
  the	
  scaffold	
  design	
  on	
  the	
  distribution	
  of	
  adhering	
   cells	
  after	
  perfusion	
  cell	
  seeding”
Enclosed is the pdf-f i le of the Paper published in Biomaterials, 2011 Apr; 32(11): 
2878-84.
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Conclusions and final remarks
1. Summary: aims and results of the experimental work   
This thesis dissertation is enclosed in the field of investigation aimed at implementing and streamlining 
skeletal tissue engineering approaches. Conventional manufacturing processes for graft generation have 
been recently challenged by new insights in basic biology, technological tools and clinical demands. Thus, 
we queried tissue engineering dogmas from all these different perspectives. 
In Chapter I, we have described for the first time the capacity of expanded, adult human MSC to generate 
frank bone through endochondral route by engineering cartilaginous template in vitro. With this protocol, we 
aimed at exemplifying the paradigm of developmental engineering in the context of bone regeneration. In 
fact, the process recapitulated the time course of events occurring during limb development, namely (i) cel-
lular condensation and hypertrophic chondrogenesis, (ii) morphogen signaling activation, (iii) formation of 
bony collar through perichondral ossification, (iv) matrix remodeling and  vascularization, and (v) formation 
of complete bone organ, including hematopoietic elements. 
Thus, with the perspective of clinical applications, we applied bioreactor technology to control, streamline 
and upscale the process.
Bioreactors could be considered a powerful tool to overcome conventional tissue manufacturing processes. 
As shown in Chapter II, bioreactor can be exploited as single closed system where all cell culture phases 
can be performed. We first focused on optimizing the first two events of the endochondral route (i.e. con-
densation and chondrogenic differentiation), which, as a matter of fact, represent the complete process of 
cartilage graft manufacturing. Therefore we hypothesised a clinical scenario for cartilage defect reconstruc-
tion, so that freshly isolated cells (at clinically relevant starting density) were first expanded directly through-
out 3D scaffold and within the bioreactor system, and, secondly induced at generating a cartilaginous like 
graft. We succeeded in engineering a graft product that is comparable with the one obtained with conven-
tional techniques and might fulfil quality release criteria for clinical application. We could develop a novel 
bioreactor based manufacturing paradigm for cartilaginous graft production, which could be applied for 
cartilage tissue engineering and used as platform for endochondral recapitulation. 
Finally, as depicted in Chapter III, we wanted to achieve control over cell condensation, throughout 3D scaf-
fold and under perfusion regime, optimizing the first step of bioreactor-based endochondral tissue engineer-
ing. Therefore we aimed at applying computational fluid dynamics model to predict cell behaviour within 
specific 5milieu and, more precisely, we generated a model system where scaffold design and computed 
perfusion regime were optimised and validated experimentally by using controlled cell distribution upon per-
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fusion seeding as readout. Tuning scaffold porosity and, therefore, velocity and shear stress profile  we 
could change cell distribution throughout the scaffold. These results highlight the paramount importance of 
bioreactor systems  as tool to monitor and control culture parameters or entire manufacturing phases.
2. Relevance of the study and future perspectives
Nowadays, the success of tissue engineering may depend on overcoming current limitations related to iden-
tification of optimal cell type, tissue manufacturing process, feasibility of clinical translation. As a matter of 
fact, in the last years the necessity of tissue engineering has been questioned, in relation to cost-
effectiveness, safety, compliance to GMP rules and potency of engineered products over existing medical 
therapies.
Developmental engineering paradigm and bioreactor technology have together the potential to remarkably 
innovate conventional regenerative medicine, from the conceptual and methodological standpoint. The 
combination of the recent progress in developmental biology as well as in bioreactor-based cell culture 
methods might provide the opportunity (i) to switch from trial-and-error approaches towards rational experi-
mental design, (ii) to create model systems to test specific scientific hypotheses, (iii) to implement and stan-
dardize conventional tissue engineering, and (iv) to ultimately target clinical applications.
The modern notion that in vitro processes should recapitulate in vivo development and repair may offer an 
alternative strategy that intrinsically contribute to implementation by defining specific boundaries, such as 
optimal cell type and critical intermediate events along the manufacturing process. 
In the first work we presented (Chapter I), endochondral route was recapitulated with adult MSC, specific 
progenitors for skeletal development and repair processes and clinically compliant cell source. 
From the molecular standpoint, key morphogenetic cross-talks were established between early and late hy-
pertrophic cells in our model system. However, spatial organization of the different cell populations was not 
exactly reproducing the pattern observed in the growth plate during development, impairing self-
organization of the tissue. Thus, next challenges in this tissue engineering field would be to unravel the 
foundations of spatio-temporal evolution of the tissue: conquering the control of cellular interactions in 4D 
will be of paramount importance for basic research and for applied tissue engineering processes. 
Moreover, orthotopic implantation in immunocompetent animal model could shed light on biomechanical 
and inflammatory/immune mechanisms that likely participate in endochondral process as well as in fracture 
healing. Further experiments targeting the role of host cells in bone forming process might pave the way to 
new generation of off-the-shelf grafts, properly instructive for events occurring upon implantation. 
Our model was based on small-scale, scaffold-free constructs that would not be relevant in a clinical sce-
nario. Further investigations are warranted for the clinical implementation of the developed paradigm. 
Scaling-up of the constructs would be the next step, possibly with the integration of the bioreactor system to 
allow in vitro simplified, streamlined and controlled culture. 
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With the attempt to ameliorate graft manufacturing process, bioreactors could be indeed considered a pow-
erful tool to substitute conventional product pipelines. If control and standardization of products and manu-
facturing processes have been so far suboptimal and might have represented an obstacle for clinical appli-
cation, bioreactors could target these weaknesses and further ameliorate the graft production. Bioreactors, 
as described in Chapter II, have been demonstrating their key role in improving seeding and culture condi-
tions, in monitoring critical culture parameters, in providing single closed system where specific culture 
phases can be performed, in up-scaling graft and production for efficient clinical translation. Moreover, as 
depicted in Chapter III, bioreactors could be exploited as model systems where culture conditions (i.e. scaf-
fold design and perfusion regime) are controlled and validated in relation to cell behaviour, in feed-back 
loop fashion: this kind of investigations may lead to a better understanding of the role of these key culture 
parameters. 
Thus, bioreactor based approaches might pave the way for the warranted “bench to bed-side” translation 
for tissue engineering products and next experiments will be focusing on the generation of stand alone 
bioreactor systems to assure GMP compliance towards the clinical application of developmental engineer-
ing paradigms for skeletal regeneration. 
Paradoxically, tissue engineering needs to identify new strategies that may go beyond tissue engineering 
itself. The recapitulation of biological and molecular events occurring during development in graft produc-
tion pipeline might suggest to overcome the traditionally envisaged implantation of preformed and mature 
grafts and to approach a more modern perspective of regenerative medicine. Path-dependence, self-
establishment and semi-autonomy of defined intermediate developmental stages might help in defining suf-
ficient and necessary level of ex-vivo tissue growth to allow and guarantee further tissue maturation and in-
tegration upon implantation. Moreover, the combination with bioreactor based cell culture might facilitate the 
understanding and optimization of in vitro processes, towards the development of simplified and streamlined 
regenerative approaches.
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